Drug Profile


Alternative Names: AFDX 116

Latest Information Update: 16 Jul 2002

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Class Benzodiazepinones; Small molecules
  • Mechanism of Action Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias; Bradycardia

Most Recent Events

  • 14 Sep 1998 No-Development-Reported for Arrhythmias in Germany (PO)
  • 14 Sep 1998 No-Development-Reported for Arrhythmias in Germany (IV)
  • 23 Jul 1998 A study has been added to the adverse events and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top